and flow DSRT, in which each cell in each well produces a data point for each marker/antibody, thus allowing to reveal population-specific drug responses: With technical questions concerning HT flow ...
The FDA approved obecabtagene autoleucel for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback